Affirma Biotech
Private Company
Total funding raised: $3.8M
Overview
Affirma Biotech is a private, preclinical-stage Spanish biotech founded in 2018, targeting severe respiratory infections through orally administered host-directed immunotherapies. The company has demonstrated in vivo proof-of-concept in influenza and bacterial infection models and has secured seed funding to advance its programs. Its strategy addresses the critical unmet needs of antimicrobial resistance and suboptimal outcomes in severe infections by modulating the patient's immune response rather than directly targeting pathogens.
Technology Platform
Development of novel, orally available small molecules that act as immune activators (host-directed therapies) to treat severe respiratory infections by modulating the patient's immune response.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Competition includes direct-acting antivirals and antibiotics, as well as other companies exploring immunomodulation for severe infections. Affirma's key differentiators are its oral small-molecule format and focus on restoring immune function in vulnerable, hospitalized patients.